Trial Profile

Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 4069327A (Primary)
Indications Shigella infections
Focus Therapeutic Use
Acronyms S4V03
Sponsors LimmaTech Biologics

Most Recent Events

09 Feb 2026 Planned End Date changed from 1 Jul 2026 to 1 Sep 2026.
09 Feb 2026 Planned primary completion date changed from 1 Feb 2026 to 1 Apr 2026.
12 Aug 2025 According to a Valneva media release, results from this study is expected in the first half of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com